Harmony Biosciences Holdings, Inc. (HRMY)
Valuation Overview•Is Harmony Biosciences Holdings, Inc. Overvalued or Undervalued?
Trading at a discount across both intrinsic cash flow and relative peer multiples, indicating a strong margin of safety.
High-quality fundamentals with a strong composite quality score of 87/100, backed by robust profitability and solvency.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Verdict: Elite compounder with fortress-level fundamentals across every core pillar.
Wall Street is highly bullish, projecting significant upside alongside robust expected earnings growth. The company currently retains all capital for reinvestment and growth rather than returning it to shareholders.
HRMY exhibits elite business quality, driven by exceptional capital efficiency and highly lucrative margins (highlighted by a massive 42.0% ROIC). This is backed by a fortress balance sheet, holding significant net cash ($513M) and minimal debt risk.
The company is driving exceptional top-line expansion (25.6% 3Y CAGR) however, earnings have severely contracted over the same period. The company maintains healthy operational efficiency with a 21.1% operating margin.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $215.4M | +21.5% | +25.6% | +40.3% | — | |
| EBITDA | $43.3M | — | +17.7% | — | — | |
| Net Income | $32.5M | +9.1% | -4.4% | — | — | |
| EPS (Diluted) | $0.55 | +8.0% | -3.0% | — | — | |
| Free Cash Flow | $27.8M | +59.1% | +34.1% | — | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 76.5% | 78.1% | 79.4% | 79.1% |
| Operating Margin | 21.1% | 27.9% | 28.0% | -326.2% |
| Net Margin | 16.2% | 20.3% | 22.7% | -349.2% |
| FCF Margin | 38.0% | 36.1% | 34.7% | -155.8% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $0.76 | $0.55 | -27.6% | ||
| Q1'26 | $0.84 | $0.38 | -54.8% | ||
| Q4'25 | $0.92 | $0.87 | -5.4% | ||
| Q3'25 | $0.78 | $0.68 | -12.8% | ||
| Q2'25 | $0.59 | $0.78 | +32.2% | ||
| Q1'25 | $0.74 | $0.85 | +14.9% | ||
| Q4'24 | $0.67 | $0.79 | +17.9% | ||
| Q3'24 | $-0.06 | $0.20 | +433.3% |
Total return is +2.5% (1Y), lagging the benchmark by -22.5%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -11.0% | -20.3% | — |
| 1Y | +2.5% | -22.5% | — |
| 3YCAGR | -3.1% | -22.1% | — |
| 5YCAGR | +1.2% | -11.4% | — |
| 10YCAGR | -1.1% | -14.6% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Harmony Biosciences Holdings, Inc. (HRMY) valuation, health, and returns.
Harmony Biosciences Holdings, Inc. is estimated to be undervalued under our discounted cash flow framework. relative multiples indicate the stock is Cheap versus peers compared to industry peers. undervalued (implying +168.3% upside to DCF intrinsic value of $89.28)
Harmony Biosciences Holdings, Inc. has multiple valuation anchors: DCF Intrinsic Value: $89.28 | Peer Relative Fair Value: $121.10 | Wall Street Analyst Target: $43.00 (implying +29.2% upside). A convergence of these signals offers higher conviction.
Harmony Biosciences Holdings, Inc. displays excellent financial health with a composite quality score of 87/100, supported by a Altman Z-Score of 4.8 (safe zone), Piotroski F-Score of 4/9, Return on Invested Capital (ROIC) of 42.0%.
Harmony Biosciences Holdings, Inc. does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Harmony Biosciences Holdings, Inc.'s current growth trajectory is Decelerating. The company achieved +21.5% 1Y revenue growth and +8.0% 1Y EPS growth, compared to its 3Y revenue CAGR of +25.6%.
Wall Street consensus is Buy based on 13 analysts, beating EPS expectations in 50% of recent quarters with a -4-quarter streak. The consensus price target represents a +29.2% change from current levels.
Investment risks for Harmony Biosciences Holdings, Inc. include: -34.5% 1-year max drawdown. Volatility risk is characterized by a beta of 0.63x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.